Quick Answer
Inmune Bio, Inc. reported Net Income Loss of -$45.93 million for the year ending 2025.
- Inmune Bio, Inc. showed a decrease of -9.2% in Net Income Loss from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Inmune Bio, Inc.'s Net Income Loss has declined by 5,424.2%.
- Historical annual values: Fiscal year 2025: -$45.93 million | Fiscal year 2024: -$42.08 million | Fiscal year 2023: -$30.01 million | Fiscal year 2022: -$27.30 million | Fiscal year 2021: -$30.34 million | Fiscal year 2020: -$12.10 million | Fiscal year 2019: -$7.68 million | Fiscal year 2018: -$12.44 million | Fiscal year 2017: -$831.5 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: